Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)

Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Lakkhana Wongsrisang, Natthinee Sudhinaraset, Sompong Vongpunsawad, Yong Poovorawan
doi: https://doi.org/10.1101/2021.09.01.21262955

Article usage

Article usage: September 2021 to December 2024

AbstractFullPdf
Sep 202166274674285
Oct 20211746133623
Nov 2021120884304
Dec 2021122441293
Jan 2022226672316
Feb 202263148135
Mar 20223302492
Apr 20221832048
May 20221741975
Jun 20221371446
Jul 2022901321
Aug 20221131131
Sep 20221151617
Oct 20221071123
Nov 20221161313
Dec 2022871118
Jan 2023991725
Feb 2023651415
Mar 202364814
Apr 202357109
May 2023561013
Jun 202358149
Jul 2023431111
Aug 2023472111
Sep 2023431310
Oct 202354912
Nov 202360106
Dec 20237977
Jan 202485125
Feb 2024781310
Mar 202452128
Apr 202426820
May 202428910
Jun 2024105611
Jul 2024106712
Aug 2024521617
Sep 2024501110
Oct 202420165
Nov 20243888
Dec 20241667
Back to top
Posted September 03, 2021.
Download PDF
Data/Code
Email
Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)
Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Lakkhana Wongsrisang, Natthinee Sudhinaraset, Sompong Vongpunsawad, Yong Poovorawan
medRxiv 2021.09.01.21262955; doi: https://doi.org/10.1101/2021.09.01.21262955
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area